CAC
PCRX icon

Cowen and Company’s Pacira BioSciences PCRX Stock Holding History

Cowen and Company’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,979
Closed -$151K – 563
2019
Q3 		$151K Buy
+3,979
New +$159K 0.04% 255

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Cowen and Company's PCRX Position: Q4 2019 in Review

Cowen and Company sold out of Pacira BioSciences (PCRX) in Q4 2019, closing a stake of 3,979 shares — an estimated $151K sold.

Cowen and Company first reported a position in PCRX in Q3 2019 and held it in 1 quarter. The position peaked at $151K in Q3 2019. 231 funds tracked by Wall St. Rank hold PCRX as of Q4 2019.

  • Cowen and Company reported no remaining Pacira BioSciences position as of Q4 2019 after selling out during the quarter.
  • Cowen and Company sold 3,979 Pacira BioSciences shares in Q4 2019, an estimated $151K.
  • Cowen and Company first reported a position in Pacira BioSciences in Q3 2019 and held it in 1 quarter.
  • Cowen and Company's Pacira BioSciences position peaked at $151K in Q3 2019.
  • 231 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2019.

Based on Cowen and Company's 13F filing for Q4 2019, filed 11 Feb 2020.